A large study of metabolomics reveals common and distinct metabolic biomarkers for type 2 diabetes, coronary heart disease, and stroke
American Journal of Epidemiology · 03.06.2025 · 194 (6) · 1650-1660
DOI: 10.1093/aje/kwae167 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Epidemiology, online erschienen am 29.06.2024. Verfasst von Yanqiang Lu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Suzhou Medical College of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Coronary Disease, Metabolomics, Stroke. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: World Health Organization, China Postdoctoral Science Foundation, Scientific Research Project of Jiangsu Health Committee.
Themen: Diabetes mellitus, Schlaganfall
Abstract (Originalsprache)
We aimed at examining the shared and unique associations of metabolites with multiple cardiometabolic diseases, including type 2 diabetes (T2D), coronary heart disease (CHD), and stroke. In this study, a total of 168 plasma metabolites were measured by high-throughput nuclear magnetic resonance spectroscopy among 98 162 participants free of T2D, CHD, and stroke at baseline. Cox proportional hazard models estimated hazard ratios for a 1-SD increase in metabolite concentration levels, and false discovery rate (at 10%) was used to correct for multiple comparisons. Over 12.1 years of follow-up on average, 3463 T2D, 6186 CHD, and 1892 stroke events were recorded. Most lipoprotein metabolites were associated with risks of T2D and CHD but not with the risk of stroke, with stronger associations for T2D than for CHD. Phospholipids within intermediate-density lipoprotein or large low-density lipoprotein particles showed positive associations with CHD and inverse associations with T2D. Metabolites indicating very small very low-density lipoprotein, histidine, creatinine, albumin, and glycoprotein acetyls were associated with risks of all 3 conditions. This large-scale metabolomics study revealed common and distinct metabolic biomarkers for T2D, CHD, and stroke, providing instrumental information to possibly implement precision medicine for preventing and treating these conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, School of Public Health, Suzhou Medical College of Soochow University, Suzhou, China.
- Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
- Department of Preventive Medicine, College of Clinical Medicine, Suzhou Vocational Health College, Suzhou, China.
ORCID-Profile: Heinz Freisling, Chaofu Ke
Förderung
- World Health Organization
- China Postdoctoral Science Foundation
- Scientific Research Project of Jiangsu Health Committee
- National Natural Science Foundation of China
Zitieren
APA
Lu, Y., Li, G., Viallon, V., Ferrari, P., Freisling, H., Qiao, Y., Shao, L., Wu, L., Ding, Y., & Ke, C. (2025). A large study of metabolomics reveals common and distinct metabolic biomarkers for type 2 diabetes, coronary heart disease, and stroke. American Journal of Epidemiology, 194(6), 1650-1660. https://doi.org/10.1093/aje/kwae167
Vancouver
Lu Y, Li G, Viallon V, Ferrari P, Freisling H, Qiao Y, et al. A large study of metabolomics reveals common and distinct metabolic biomarkers for type 2 diabetes, coronary heart disease, and stroke. American Journal of Epidemiology. 2025;194(6):1650-1660. doi:10.1093/aje/kwae167
BibTeX
@article{Lu2025,
author = {Lu, Yanqiang and Li, Guochen and Viallon, Vivian and Ferrari, Pietro and Freisling, Heinz and Qiao, Yanan and Shao, Liping and Wu, Luying and Ding, Yi and Ke, Chaofu},
title = {A large study of metabolomics reveals common and distinct metabolic biomarkers for type 2 diabetes, coronary heart disease, and stroke},
journal = {American Journal of Epidemiology},
year = {2025},
volume = {194},
number = {6},
pages = {1650--1660},
doi = {10.1093/aje/kwae167}
}
EUVIMED